

<p style="text-align: center;">Declaration Under 37 C.F.R §1.132</p> <p>Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450</p>	Attorney Docket Confirmation No.	STAN-131 8224
	First Named Inventor	Briesewitz
	Application Number	09/716,842
	Filing Date	November 17, 2000
	Group Art Unit	1644
	Examiner Name	HUYNH, PHUONG NEON
	Title	"TARGETED BIFUNCTIONAL MOLECULES AND THERAPIES BASED THEREON"

Dear Sir:

We, Dr. Thomas Wandless, Dr. Roger Briesewitz and Dr. Gerald Crabtree, do hereby declare as follows:

We are co-inventors of the above captioned patent application.

We are also co-inventors of U.S. Patent No. 6,372,712, along with Gregory Thomas Ray and Kurt Vogel.

We understand that U.S. Patent No. 6,372,712 is being cited by the Patent Office to anticipate the claims of the above captioned application pursuant to 35 U.S.C. §102(e).

U.S. Patent No. 6,372,712 discloses bifunctional molecules and their use in applications for enhancing one or more of a given drug's affinity, specificity or selectivity for its target.

The claims of U.S. Patent No. 6,372,712 are all directed to the bifunctional compounds disclosed in the patent, and the inventorship of these claims has been determined to be as listed on the face of U.S. Patent No. 6,372,712.

In contrast to the composition of matter claims of U.S. Patent No. 6,372,712, the claims of the above-captioned application are directed to a particular use of bifunctional molecules, i.e., methods of directing the biodistribution of a drug that binds to a protein target. To the extent that this particular application is disclosed in the specification of U.S. Patent No. 6,372,712 (if at all), this particular applications was not conceived by either of Gregory Ray or Kurt Vogel.

Accordingly, we hereby declare that we are the sole inventors of the subject matter disclosed in the cited 6,372,712 patent and relied on in the above-summarized rejection.

We are also co-inventors of U.S. Patent No. 6,921,531, along with Gregory Thomas Ray and Kurt Vogel.

We understand that U.S. Patent No. 6,921,531 is being cited by the Patent Office to anticipate the claims of the above captioned application pursuant to 35 U.S.C. §102(e).

U.S. Patent No. 6,921,531 discloses bifunctional molecules and their use in applications for enhancing one or more of a given drug's affinity, specificity or selectivity for its target.


The claims of U.S. Patent No. 6,921,531 are variously directed to improved methods of administering a drug to a host in need of said drug, methods of producing a tripartite complex in a mammalian host, methods of producing an intracellular tripartite complex in a mammalian host, and methods of enhancing the selectivity of a drug for an intracellular drug target in a first cell as compared to a second cell containing the drug target. The inventorship of these claims has been determined to be as listed on the face of U.S. Patent No. 6,921,531.

In contrast to the method claims of U.S. Patent No. 6,921,531, the claims of the above-captioned application are directed to a different use of bifunctional molecules, i.e., methods of directing the biodistribution of a drug that binds to a protein target. To the extent that this particular application was disclosed in the specification of U.S. Patent No. 6,921,531 (if at all), this particular application was not conceived by either of Gregory Ray or Kurt Vogel.

Accordingly, we hereby declare that we are the sole inventors of the subject matter disclosed in the cited patent and relied on in the above-summarized rejection.

We hereby declare that all statements made herein of our own knowledge are true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: 6 Nov 2008

Respectfully submitted,
By 
Thomas Wandless, Ph.D.

Date: _____

By _____
Roger Briesewitz, Ph.D.

Date: _____

By _____
Gerald Crabtree, Ph.D.